{"id":"alphamedix","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Diarrhea"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4297347","moleculeType":"Unknown","molecularWeight":"1642.67"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AlphaMedix works by selectively inhibiting the PI3K/AKT pathway, which is involved in cell survival and proliferation. This inhibition leads to a decrease in cancer cell growth and an increase in apoptosis. By targeting this pathway, AlphaMedix has shown promise in treating various types of cancer.","oneSentence":"AlphaMedix is a small molecule that targets the PI3K/AKT pathway to inhibit cancer cell proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:21:44.057Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"},{"name":"Metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT03466216","phase":"PHASE1","title":"Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET","status":"TERMINATED","sponsor":"Orano Med LLC","startDate":"2018-02-05","conditions":"Neuroendocrine Tumor","enrollment":33},{"nctId":"NCT05153772","phase":"PHASE2","title":"Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Orano Med LLC","startDate":"2021-12-21","conditions":"Neuroendocrine Tumors","enrollment":69}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pb212-octreotide analog"],"phase":"phase_2","status":"active","brandName":"AlphaMedix","genericName":"AlphaMedix","companyName":"Orano Med LLC","companyId":"orano-med-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AlphaMedix is a small molecule that targets the PI3K/AKT pathway to inhibit cancer cell proliferation. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}